Antibody Contract Manufacturing Market to Cross USD 47 billion by 2035 | Roots Analysis
The global antibody contract manufacturing market size is growing at a CAGR of 10.04% in the forecast period 2024-2035.
The antibody contract manufacturing market is witnessing robust growth, driven by several key factors such as rising demand for biologics, prevalence of chronic diseases and shifting trend towards personalized medicine. This dominance is expected to persist, as advanced antibodies such as bispecific antibodies and antibody fragments gain prominence.
However, the challenges inherent in development and production of biologics have led to a widespread practice of outsourcing antibody manufacturing operations. As a result, the market for antibody contract manufacturing or monoclonal antibody contract manufacturing is fiercely competitive, featuring companies of various sizes. It is worth mentioning that some players are engaged in providing comprehensive solutions, from antibody development to commercial production however, sponsors are likely to rely on contract service providers owing to substantial costs and time-intensive process of setting up the infrastructure. Consequently, CMOs are expanding their capacities and capabilities in order to consolidate their position in the market and meet the escalating demand.
According to the latest market research study by Roots Analysis on the global antibody contract manufacturing market size is projected to reach USD 47 billion by 2035 from USD 16.4 billion in 2024, growing at a CAGR of 10.04% in the forecast period 2024-2035.
Market Segments
Based on the type of antibody manufactured, the market is segmented into monoclonal antibodies and bispecific antibodies.
§ The monoclonal antibodies segment is likely to capture the largest revenue share of 97% in the antibody contract manufacturing market, in 2024.
§ Further, the bispecific antibodies segment is anticipated to witness the highest annual growth rate of 12.83% during the forecast period.
Based on the type of expression system used, the market is segmented into mammalian expression and microbial expression.
§ The mammalian expression system is likely to capture the largest revenue share of close to 85% in the antibody contract manufacturing market, in 2024.
§ The mammalian expression system is anticipated to witness the highest annual growth rate of around 10.4% during the forecast period.
Based on the scale of operation, the market is segmented into commercial and clinical scale.
§ Antibody contract manufacturing at commercial scale is likely to capture the largest revenue share of 96% in 2024.
§ The antibody contract manufacturing market at commercial scale is anticipated to witness a market growth rate of 10.2% annually during the forecast period.
Based on the Geographical Regions, the market is segmented into North America, Europe, Asia, Latin America and Middle East and North Africa.
§ North America dominated the antibody contract manufacturing market and accounted for the largest revenue share of 54% in 2024.
§ In Asia, the antibody contract manufacturing market is anticipated to grow at a higher growth rate of 11.23% during the forecast period.
Market Key Players
Examples of key companies engaged in antibody contract manufacturing market (which have also been profiled in this market report; the complete list of companies is available in the full report) include AGC Biologics, Aldevron, Emergent BioSolutions, Eurofins CDMO, FUJIFILM Diosynth Biotechnologies, KBI Biopharma, Lonza, Nitto Avecia Pharma Services, Novasep, Pierre Fabre, Samsung BioLogics, Synthon
Market Regional Outlook
Based on the key geographical regions, the antibody contract manufacturing market can be segmented into five major regions, including North America, Europe, Asia, Latin America and Middle East and North Africa. Led by the US, North America is anticipated to capture the majority share of the antibody contract manufacturing market in 2024, and this trend is likely to remain unchanged during the forecast period. The biology manufacturing industry in Asia is accounted to be the fastest-growing segment of the market.
Key Report Takeaways
§ Presently, 129 service providers worldwide, are engaged in offering services for various antibodies; close to 40% of these stakeholders are headquartered in the North America
§ 60% of players engaged in this domain have the capabilities to manufacture antibodies at all scales of operation. This indicates that stakeholders are actively striving as one stop shops and provide end-to-end services to customers worldwide
§ 95% of the contract manufacturers are involved in the production of monoclonal antibodies, followed by those manufacturing bispecific antibodies (27%).
§ Presently, most widely used expression systems for manufacturing antibodies are mammalian systems (94%) followed by microbial systems (57%). This can be attributed to the fact that antibodies produced in mammalian cells are more likely to resemble those found in humans, both in terms of structure and function.
§ The demand for antibody contract manufacturing market is anticipated to grow at a CAGR of 6.3%
About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. All reports provided by us are structured in a way that enables the reader to develop a thorough perspective on the subject given. Apart from writing reports on identified areas, we provide bespoke research / consulting services dedicated to serving our clients in the best possible way.
Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
+44 (122) 391 1091
Email: sales@rootsanalysis.com
What's Your Reaction?
